Ribomic, Inc. (4591) AI Stock Analysis

• Market Cap: ¥4.42B
• Dividend Yield: N/A
• Average Volume (3M): 1.41M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: -96.64%
• EPS Growth: 8.92%
• Country: JP
• Employees: 24
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -6.33
• Shares Outstanding: 44,613,940
• 10 Day Avg. Volume: 1,453,570
• 30 Day Avg. Volume: 1,414,656
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: ―

Ribomic, Inc. faces significant financial challenges with declining revenues and persistent losses, indicating operational inefficiencies and financial instability. The technical analysis also suggests lack of strong momentum, and the valuation metrics highlight potential overvaluation concerns. The absence of mitigating factors from earnings calls or corporate events underscores the need for substantial operational improvements to enhance the stock's outlook.

Ribomic, Inc. Business Overview & Revenue Model

Company Description

Ribomic, Inc. (4591) is a biotechnology company specializing in the development of aptamer-based therapeutics. Aptamers are short, single-stranded DNA or RNA molecules that can bind to specific targets, such as proteins, with high affinity and specificity. Ribomic focuses on creating innovative treatments for a variety of diseases, including ocular disorders, through its proprietary RiboART platform. The company operates within the pharmaceutical and biotechnology sectors, advancing its pipeline of products towards clinical trials and potential commercialization.

How the Company Makes Money

Ribomic, Inc. generates revenue primarily through research and development partnerships, licensing agreements, and potential milestone and royalty payments associated with its aptamer-based therapeutics. The company collaborates with pharmaceutical and biotechnology firms to co-develop and commercialize its drug candidates, leveraging its proprietary technology platform. These partnerships often involve upfront payments, as well as contingent payments based on the achievement of specific development, regulatory, or sales milestones. Additionally, once the products are commercialized, Ribomic stands to earn royalties based on sales, further contributing to its revenue.

Ribomic, Inc. Financial Statement Overview

Summary

Ribomic, Inc. is struggling financially with declining revenues and persistent net losses, leading to negative profit margins. Despite a strong equity position and no debt, the inability to generate positive cash flow or profits indicates underlying operational inefficiencies and risks to financial stability.

Income Statement

Ribomic, Inc. shows declining revenues with TTM revenue at $2.1M, down from $65.9M the previous year. Gross profit margin is negative at -82.3%, indicating high cost relative to revenue. Net profit margin is also negative, reflecting consistent net losses. The EBIT and EBITDA margins are significantly negative, pointing to operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The company's balance sheet shows strong equity with no debt, resulting in a debt-to-equity ratio of 0. The equity ratio is high at 95.9%, indicating strong asset backing by equity. However, the consistent net losses are concerning, affecting return on equity negatively. While the company has a solid cash position, the absence of debt financing may limit growth potential.

Cash Flow

Free cash flow is zero in the latest TTM, indicating no surplus cash generation. The operating cash flow to net income ratio cannot be calculated due to zero operating cash flow. Historical free cash flow has been negative, showing cash outflows from operations exceeding inflows. The lack of positive cash flow trends raises concerns about financial sustainability.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.11M	0.00	65.97M	80.91M	91.96M
Gross Profit	2.11M	-10.50M	65.97M	80.91M	91.96M
EBITDA	-1.02B	-1.01B	-1.79B	-1.73B	-1.21B
Net Income	-1.02B	-1.02B	-1.65B	-1.68B	-1.19B
Balance Sheet
Total Assets	3.19B	3.55B	4.58B	4.95B	6.12B
Cash, Cash Equivalents and Short-Term Investments	3.04B	3.40B	4.33B	4.70B	5.84B
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	142.21M	155.81M	199.30M	260.53M	116.96M
Stockholders Equity	3.04B	3.39B	4.38B	4.69B	6.00B
Cash Flow
Free Cash Flow	-1.03B	-955.48M	-1.73B	-1.51B	-1.15B
Operating Cash Flow	-999.00M	-932.76M	-1.71B	-1.50B	-1.15B
Investing Cash Flow	67.18M	177.27M	276.35M	689.56M	-1.70B
Financing Cash Flow	667.26M	27.65M	1.33B	354.72M	4.99B

Ribomic, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 99.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4591, the sentiment is Neutral. The current price of 99 is below the 20-day moving average (MA) of 106.70, below the 50-day MA of 100.14, and above the 200-day MA of 91.33, indicating a neutral trend. The MACD of -1.37 indicates Positive momentum. The RSI at 45.35 is Neutral, neither overbought nor oversold. The STOCH value of 20.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4591.

Ribomic, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4503	74 Outperform	$2.84T	34.60	5.46%	4.69%	14.29%	368.64%
4578	74 Outperform	$3.93T	9.78	15.51%	1.74%	10.17%	226.18%
4523	67 Neutral	¥1.20T	25.96	5.34%	3.76%	6.42%	10.82%
4502	67 Neutral	$6.68T	48.36	1.99%	4.65%	1.52%	-8.68%
Sector *	65 Neutral	¥351.75B	9.37	-3.16%	2.47%	11.67%	-10.80%
4563	56 Neutral	¥26.12B	―	-193.61%	―	179.79%	-204.13%
4591	37 Underperform	¥4.42B	―		―	-96.64%	8.92%

Ribomic, Inc. Corporate Events

Ribomic Inc. Reports Improved Financial Results for Nine Months Ending December 2024

Ribomic Inc. has reported its non-consolidated financial results for the nine months ending December 31, 2024, showing a reduction in losses compared to the same period the previous year. The company maintains a strong equity ratio of over 95% and continues to forecast a stable financial outlook for the full year, despite no expected changes in dividends.